Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6ZIO

CRYSTAL STRUCTURE OF NRAS (C118S) IN COMPLEX WITH GDP

Summary for 6ZIO
Entry DOI10.2210/pdb6zio/pdb
DescriptorGTPase NRas, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, ... (4 entities in total)
Functional Keywordsgtpase, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight40183.75
Authors
Kessler, D.,Fischer, G.,Boettcher, J. (deposition date: 2020-06-26, release date: 2020-08-19, Last modification date: 2024-01-31)
Primary citationKessler, D.,Bergner, A.,Bottcher, J.,Fischer, G.,Dobel, S.,Hinkel, M.,Mullauer, B.,Weiss-Puxbaum, A.,McConnell, D.B.
Drugging all RAS isoforms with one pocket.
Future Med Chem, 12:1911-1923, 2020
Cited by
PubMed Abstract: Activating mutations in the three human RAS genes, , and , are among the most common oncogenic drivers in human cancers. Covalent KRAS inhibitors, which bind to the switch II pocket in the 'off state' of KRAS, represent the first direct KRAS drugs that entered human clinical trials. However, the remaining 85% of non-KRAS-driven cancers remain undrugged as do NRAS and HRAS and no drugs targeting the 'on state' have been discovered so far. The switch I/II pocket is a second pocket for which the nanomolar inhibitor BI-2852 has been discovered. Here, we elucidate inhibitor binding modes in KRAS, NRAS and HRAS on and off and discuss future strategies to drug all RAS isoforms with this one pocket.
PubMed: 32779487
DOI: 10.4155/fmc-2020-0221
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.55 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon